{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:09:04Z","timestamp":1789024144223,"version":"build-2803163510"},"reference-count":66,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T00:00:00Z","timestamp":1769990400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"BeOne Medicines Ltd"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s12325-025-03486-z","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T08:19:25Z","timestamp":1770020365000},"page":"1034-1059","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Have Fixed-Duration (FD) Regimens Delivered on Their Promise in Chronic Lymphocytic Leukemia and What Is the Future of FD Regimens? A Narrative Review"],"prefix":"10.1007","volume":"43","author":[{"given":"John N.","family":"Allan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,2]]},"reference":[{"key":"3486_CR1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16112011","author":"A Fresa","year":"2024","unstructured":"Fresa A, Innocenti I, Tomasso A, et al. Treatment sequencing in chronic lymphocytic leukemia in 2024: where we are and where we are headed. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16112011.","journal-title":"Cancers (Basel)"},{"key":"3486_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","volume":"124","author":"N Pflug","year":"2014","unstructured":"Pflug N, Bahlo J, Shanafelt TD, et al. Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia. Blood. 2014;124:49\u201362.","journal-title":"Blood"},{"key":"3486_CR3","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131:2745\u201360.","journal-title":"Blood"},{"key":"3486_CR4","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1182\/bloodadvances.2022009040","volume":"7","author":"R Griffin","year":"2023","unstructured":"Griffin R, Wiedmeier-Nutor JE, Parikh SA, et al. Differential prognosis of single and multiple TP53 abnormalities in high-count MBL and untreated CLL. Blood Adv. 2023;7:3169\u201379.","journal-title":"Blood Adv"},{"key":"3486_CR5","doi-asserted-by":"publisher","first-page":"1848","DOI":"10.1182\/blood.V94.6.1848","volume":"94","author":"TJ Hamblin","year":"1999","unstructured":"Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood. 1999;94:1848\u201354.","journal-title":"Blood"},{"key":"3486_CR6","unstructured":"AbbVie Inc. Calquence prescribing information. https:\/\/drd9vrdh9yh09.cloudfront.net\/50fd68b9-106b-4550-b5d0-12b045f8b184\/e2a005a7-65a0-4388-a671-dc887815a938\/e2a005a7-65a0-4388-a671-dc887815a938_viewable_rendition__v.pdf. Accessed 5 Aug 2025."},{"key":"3486_CR7","unstructured":"BeOne Medicines USA Inc. Brukinsa2025. https:\/\/d1e94vsyskgtht.cloudfront.net\/brukinsa\/pdfs\/brukinsa-prescribing-information.pdf. Accessed 29 June 2025."},{"key":"3486_CR8","doi-asserted-by":"publisher","first-page":"7923","DOI":"10.1021\/acs.jmedchem.9b00687","volume":"62","author":"Y Guo","year":"2019","unstructured":"Guo Y, Liu Y, Hu N, et al. Discovery of zanubrutinib (BGB-3111), a novel, potent, and selective covalent inhibitor of Bruton\u2019s tyrosine kinase. J Med Chem. 2019;62:7923\u201340.","journal-title":"J Med Chem"},{"key":"3486_CR9","doi-asserted-by":"publisher","first-page":"3734","DOI":"10.1158\/1078-0432.CCR-16-1446","volume":"23","author":"V Patel","year":"2017","unstructured":"Patel V, Balakrishnan K, Bibikova E, et al. Comparison of acalabrutinib, a selective Bruton tyrosine kinase inhibitor, with ibrutinib in chronic lymphocytic leukemia cells. Clin Cancer Res. 2017;23:3734\u201343.","journal-title":"Clin Cancer Res"},{"key":"3486_CR10","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1200\/JCO.22.00510","volume":"41","author":"P Hillmen","year":"2023","unstructured":"Hillmen P, Eichhorst B, Brown JR, et al. Zanubrutinib versus ibrutinib in relapsed\/refractory chronic lymphocytic leukemia and small lymphocytic lymphoma: interim analysis of a randomized phase\u00a0III trial. J Clin Oncol. 2023;41:1035\u201345.","journal-title":"J Clin Oncol"},{"key":"3486_CR11","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1200\/JCO.21.01210","volume":"39","author":"JC Byrd","year":"2021","unstructured":"Byrd JC, Hillmen P, Ghia P, et al. Acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase\u00a0III trial. J Clin Oncol. 2021;39:3441\u201352.","journal-title":"J Clin Oncol"},{"key":"3486_CR12","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1056\/NEJMoa2211582","volume":"388","author":"JR Brown","year":"2023","unstructured":"Brown JR, Eichhorst B, Hillmen P, et al. Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2023;388:319\u201332.","journal-title":"N Engl J Med"},{"key":"3486_CR13","doi-asserted-by":"publisher","first-page":"2861","DOI":"10.1182\/bloodadvances.2023012142","volume":"8","author":"AS Kittai","year":"2024","unstructured":"Kittai AS, Allan JN, James D, et al. An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL. Blood Adv. 2024;8:2861\u20139.","journal-title":"Blood Adv"},{"key":"3486_CR14","doi-asserted-by":"publisher","DOI":"10.1177\/17588359251340554","volume":"17","author":"M Shadman","year":"2025","unstructured":"Shadman M, Brown JR, Williams R, et al. Efficacy of zanubrutinib versus acalabrutinib for relapsed or refractory chronic lymphocytic leukemia (R\/R CLL): a matching-adjusted indirect comparison (MAIC). Ther Adv Med Oncol. 2025;17:17588359251340554.","journal-title":"Ther Adv Med Oncol"},{"key":"3486_CR15","volume":"25","author":"M Shadman","year":"2025","unstructured":"Shadman M, Yang K, Xu S, Williams R, Munir T. CLL-1029: a network meta-analysis of efficacy of zanubrutinib vs fixed-duration acalabrutinib plus venetoclax in treatment-na\u00efve chronic lymphocytic leukemia. Clin Lymphoma Myeloma Leuk. 2025;25:S535-6.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3486_CR16","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1080\/17512433.2021.1978288","volume":"14","author":"CS Tam","year":"2021","unstructured":"Tam CS, Ou YC, Trotman J, Opat S. Clinical pharmacology and PK\/PD translation of the second-generation Bruton\u2019s tyrosine kinase inhibitor, zanubrutinib. Expert Rev Clin Pharmacol. 2021;14:1329\u201344.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"3486_CR17","unstructured":"Swaminathan M. Is fixed-duration therapy the new standard of care in frontline chronic lymphocytic leukemia? Targeted Oncology. 2023. https:\/\/www.targetedonc.com\/view\/is-fixed-duration-therapy-the-new-standard-of-care-in-frontline-chronic-lymphocytic-leukemia-. Accessed 4 Aug 2025."},{"key":"3486_CR18","doi-asserted-by":"publisher","first-page":"1924","DOI":"10.1182\/blood.2024024631","volume":"144","author":"O Al-Sawaf","year":"2024","unstructured":"Al-Sawaf O, Robrecht S, Zhang C, et al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the randomized phase\u00a03 CLL14 study. Blood. 2024;144:1924\u201335.","journal-title":"Blood"},{"key":"3486_CR19","unstructured":"AbbVie. AbbVie receives European Commission approval of VENCLYXTO\u00ae combination regimen for patients with previously-untreated chronic lymphocytic leukemia. 2020. https:\/\/news.abbvie.com\/2020-03-12-AbbVie-Receives-European-Commission-Approval-of-VENCLYXTO-R-Combination-Regimen-for-Patients-with-Previously-Untreated-Chronic-Lymphocytic-Leukemia. Accessed 5 Aug 2025."},{"key":"3486_CR20","unstructured":"AbbVie. AbbVie receives European Commission Approval of VENCLYXTO\u00ae (venetoclax) plus rituximab for the treatment of patients with chronic lymphocytic leukemia who have received at least one prior therapy. 2018. https:\/\/news.abbvie.com\/2018-11-01-AbbVie-Receives-European-Commission-Approval-of-VENCLYXTO-R-venetoclax-Plus-Rituximab-for-the-Treatment-of-Patients-with-Chronic-Lymphocytic-Leukemia-Who-Have-Received-at-Least-One-Prior-Therapy. Accessed 5 Aug 2025."},{"key":"3486_CR21","doi-asserted-by":"publisher","first-page":"4042","DOI":"10.1200\/JCO.20.00948","volume":"38","author":"AP Kater","year":"2020","unstructured":"Kater AP, Wu JQ, Kipps T, et al. Venetoclax plus rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO phase\u00a0III study. J Clin Oncol. 2020;38:4042\u201354.","journal-title":"J Clin Oncol"},{"key":"3486_CR22","unstructured":"Johnson&Johnson. European Commission approves IMBRUVICA\u00ae (ibrutinib) in a fixed-duration combination regimen for adult patients with previously untreated chronic lymphocytic leukaemia (CLL). 2022. https:\/\/www.jnj.com\/media-center\/press-releases\/european-commission-approves-imbruvica-ibrutinib-in-a-fixed-duration-combination-regimen-for-adult-patients-with-previously-untreated-chronic-lymphocytic-leukaemia-cll. Accessed 5 Aug 2025."},{"key":"3486_CR23","doi-asserted-by":"publisher","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","volume":"24","author":"CU Niemann","year":"2023","unstructured":"Niemann CU, Munir T, Moreno C, et al. Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase\u00a03 trial. Lancet Oncol. 2023;24:1423\u201333.","journal-title":"Lancet Oncol"},{"key":"3486_CR24","doi-asserted-by":"publisher","first-page":"3278","DOI":"10.1182\/blood.2021014488","volume":"139","author":"CS Tam","year":"2022","unstructured":"Tam CS, Allan JN, Siddiqi T, et al. Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort. Blood. 2022;139:3278\u201389.","journal-title":"Blood"},{"key":"3486_CR25","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1056\/NEJMoa2409804","volume":"392","author":"JR Brown","year":"2025","unstructured":"Brown JR, Seymour JF, Jurczak W, et al. Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med. 2025;392:748\u201362.","journal-title":"N Engl J Med"},{"key":"3486_CR26","unstructured":"Barrett D. European Commission approves fixed-duration acalabrutinib + venetoclax \u00b1 obinutuzumab for adult patients with previously untreated CLL. LymphomaHub. 2025. https:\/\/lymphomahub.com\/medical-information\/european-commission-approves-fixed-duration-acalabrutinib-venetoclax-obinutuzumab-for-adult-patients-with-previously-untreated-cll. Accessed 5 Aug 2025."},{"key":"3486_CR27","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2515458","author":"O Al-Sawaf","year":"2025","unstructured":"Al-Sawaf O, Stumpf J, Zhang C, et al. Fixed-duration versus continuous treatment for chronic lymphocytic leukemia. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/NEJMoa2515458.","journal-title":"N Engl J Med"},{"key":"3486_CR28","unstructured":"Genentech. FDA approves new fixed-duration treatment option for previously untreated chronic lymphocytic leukemia. 2019. https:\/\/www.gene.com\/media\/news-features\/fda-approves-new-fixed-duration-treatment-option-for-previously-untreated-chronic-lymphocytic-leukemia. Accessed 5 Aug 2025."},{"key":"3486_CR29","unstructured":"AbbVie. AbbVie announces U.S. FDA approval of VENCLEXTA\u00ae (venetoclax tablets) in combination with rituximab as a fixed duration treatment for chronic lymphocytic leukemia or small lymphocytic lymphoma patients who have received one prior therapy. 2018. https:\/\/news.abbvie.com\/2018-06-08-AbbVie-Announces-U-S-FDA-Approval-of-VENCLEXTA-R-venetoclax-tablets-in-Combination-with-Rituximab-as-a-Fixed-Duration-Treatment-for-Chronic-Lymphocytic-Leukemia-or-Small-Lymphocytic-Lymphoma-Patients-Who-Have-Received-One-Prior-Therapy. Accessed 5 Aug 2025."},{"key":"3486_CR30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199175","volume":"144","author":"JD Soumerai","year":"2024","unstructured":"Soumerai JD, Cheah CY, Anderson MA, et al. Sonrotoclax and zanubrutinib as frontline treatment for CLL demonstrates high MRD clearance rates with good tolerability: data from an ongoing phase\u00a01\/1b study BGB-11417-101. Blood. 2024;144:1012.","journal-title":"Blood"},{"key":"3486_CR31","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1200\/JCO-24-02503","volume":"43","author":"MS Davids","year":"2025","unstructured":"Davids MS, Ryan CE, Lampson BL, et al. Phase\u00a0II study of acalabrutinib, venetoclax, and obinutuzumab in a treatment-naive chronic lymphocytic leukemia population enriched for high-risk disease. J Clin Oncol. 2025;43:788\u201399.","journal-title":"J Clin Oncol"},{"key":"3486_CR32","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1182\/blood.2024024510","volume":"144","author":"LE Roeker","year":"2024","unstructured":"Roeker LE, Woyach JA, Cheah CY, et al. Fixed-duration pirtobrutinib plus venetoclax with or without rituximab in relapsed\/refractory CLL: the phase\u00a01b BRUIN trial. Blood. 2024;144:1374\u201386.","journal-title":"Blood"},{"key":"3486_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37648-w","volume":"14","author":"O Al-Sawaf","year":"2023","unstructured":"Al-Sawaf O, Zhang C, Jin HY, et al. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. Nat Commun. 2023;14:2147.","journal-title":"Nat Commun"},{"key":"3486_CR34","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","volume":"380","author":"K Fischer","year":"2019","unstructured":"Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380:2225\u201336.","journal-title":"N Engl J Med"},{"key":"3486_CR35","doi-asserted-by":"publisher","first-page":"4049","DOI":"10.1200\/JCO.21.01181","volume":"39","author":"O Al-Sawaf","year":"2021","unstructured":"Al-Sawaf O, Zhang C, Lu T, et al. Minimal residual disease dynamics after venetoclax-obinutuzumab treatment: extended off-treatment follow-up from the randomized CLL14 study. J Clin Oncol. 2021;39:4049\u201360.","journal-title":"J Clin Oncol"},{"key":"3486_CR36","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","volume":"21","author":"O Al-Sawaf","year":"2020","unstructured":"Al-Sawaf O, Zhang C, Tandon M, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase\u00a03 trial. Lancet Oncol. 2020;21:1188\u2013200.","journal-title":"Lancet Oncol"},{"key":"3486_CR37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1182\/blood-2020-136977","volume":"136","author":"O Al-Sawaf","year":"2020","unstructured":"Al-Sawaf O, Zhang C, Robrecht S, et al. Clonal dynamics after venetoclax-obinutuzumab therapy: novel insights from the randomized, phase\u00a03 CLL14 trial. Blood. 2020;136:22\u20133.","journal-title":"Blood"},{"key":"3486_CR38","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200006","volume":"1","author":"AP Kater","year":"2022","unstructured":"Kater AP, Owen C, Moreno C, et al. Fixed-duration ibrutinib-venetoclax in patients with chronic lymphocytic leukemia and comorbidities. NEJM Evid. 2022;1:EVIDoa2200006.","journal-title":"NEJM Evid"},{"key":"3486_CR39","doi-asserted-by":"publisher","first-page":"3853","DOI":"10.1200\/JCO.21.00807","volume":"39","author":"WG Wierda","year":"2021","unstructured":"Wierda WG, Allan JN, Siddiqi T, et al. Ibrutinib plus venetoclax for first-line treatment of chronic lymphocytic leukemia: primary analysis results from the minimal residual disease cohort of the randomized phase\u00a0II CAPTIVATE study. J Clin Oncol. 2021;39:3853\u201365.","journal-title":"J Clin Oncol"},{"key":"3486_CR40","unstructured":"Al-Sawaf O, Stumpf J, Zhang C, et al. Fixed-duration versus continuous targeted treatment for previously untreated chronic lymphocytic leukemia: results from the randomized CLL17 trial. In: 67th ASH annual meeting, December 6\u20139, 2025, Orlando, FL; 2025."},{"key":"3486_CR41","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","volume":"378","author":"JF Seymour","year":"2018","unstructured":"Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia. N Engl J Med. 2018;378:1107\u201320.","journal-title":"N Engl J Med"},{"key":"3486_CR42","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1200\/JCO.18.01580","volume":"37","author":"AP Kater","year":"2019","unstructured":"Kater AP, Seymour JF, Hillmen P, et al. Fixed duration of venetoclax-rituximab in relapsed\/refractory chronic lymphocytic leukemia eradicates minimal residual disease and prolongs survival: post-treatment follow-up of the MURANO phase\u00a0III study. J Clin Oncol. 2019;37:269\u201377.","journal-title":"J Clin Oncol"},{"key":"3486_CR43","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024025525","author":"AP Kater","year":"2025","unstructured":"Kater AP, Harrup RA, Kipps TJ, et al. The MURANO study: final analysis and retreatment\/crossover substudy results of VenR for patients with relapsed\/refractory CLL. Blood. 2025. https:\/\/doi.org\/10.1182\/blood.2024025525.","journal-title":"Blood"},{"key":"3486_CR44","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.1056\/NEJMra0904569","volume":"364","author":"SC Howard","year":"2011","unstructured":"Howard SC, Jones DP, Pui CH. The tumor lysis syndrome. N Engl J Med. 2011;364:1844\u201354.","journal-title":"N Engl J Med"},{"key":"3486_CR45","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1111\/bjh.15232","volume":"182","author":"CL Freeman","year":"2018","unstructured":"Freeman CL, Sehn LH. A tale of two antibodies: obinutuzumab versus rituximab. Br J Haematol. 2018;182:29\u201345.","journal-title":"Br J Haematol"},{"key":"3486_CR46","doi-asserted-by":"publisher","first-page":"2624","DOI":"10.1182\/bloodadvances.2021004629","volume":"5","author":"A Vijenthira","year":"2021","unstructured":"Vijenthira A, Gong I, Betschel SD, Cheung M, Hicks LK. Vaccine response following anti-CD20 therapy: a systematic review and meta-analysis of 905 patients. Blood Adv. 2021;5:2624\u201343.","journal-title":"Blood Adv"},{"key":"3486_CR47","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.clml.2016.09.010","volume":"17","author":"S Yun","year":"2017","unstructured":"Yun S, Vincelette ND, Acharya U, Abraham I. Risk of atrial fibrillation and bleeding diathesis associated with ibrutinib treatment: a systematic review and pooled analysis of four randomized controlled trials. Clin Lymphoma Myeloma Leuk. 2017;17:31-7.e13.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3486_CR48","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211228","volume":"14","author":"D Caldeira","year":"2019","unstructured":"Caldeira D, Alves D, Costa J, Ferreira JJ, Pinto FJ. Ibrutinib increases the risk of hypertension and atrial fibrillation: systematic review and meta-analysis. PLoS ONE. 2019;14:e0211228.","journal-title":"PLoS ONE"},{"key":"3486_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2019-001049","volume":"6","author":"F Baptiste","year":"2019","unstructured":"Baptiste F, Cautela J, Ancedy Y, et al. High incidence of atrial fibrillation in patients treated with ibrutinib. Open Heart. 2019;6:e001049.","journal-title":"Open Heart"},{"key":"3486_CR50","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.6953","volume":"13","author":"SF Huntington","year":"2024","unstructured":"Huntington SF, de Nigris E, Puckett JT, et al. Real-world analysis of adverse event rates after initiation of ibrutinib among Medicare beneficiaries with chronic lymphocytic leukemia. Cancer Med. 2024;13:e6953.","journal-title":"Cancer Med"},{"key":"3486_CR51","unstructured":"Munir T, Hernandez-Rivas J-A, Tedeschi A, et al., editors. Cross-study comparison of ibrutinib in combination with venetoclax (I+V) vs acalabrutinib in combination with venetoclax (A+V) in subjects with previously untreated chronic lymphocytic leukemia (CLL). European Hematology Association Annual Congress; 2025 June 12\u201315, Milan, Italy; 2025."},{"key":"3486_CR52","doi-asserted-by":"publisher","first-page":"2180","DOI":"10.1056\/NEJMc2503839","volume":"392","author":"M Mohty","year":"2025","unstructured":"Mohty M, Kharfan-Dabaja MA. Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med. 2025;392:2180\u20131.","journal-title":"N Engl J Med"},{"key":"3486_CR53","doi-asserted-by":"publisher","first-page":"7836","DOI":"10.1021\/acs.jmedchem.4c00027","volume":"67","author":"Y Guo","year":"2024","unstructured":"Guo Y, Xue H, Hu N, et al. Discovery of the clinical candidate sonrotoclax (BGB-11417), a highly potent and selective inhibitor for both WT and G101V mutant Bcl-2. J Med Chem. 2024;67:7836\u201358.","journal-title":"J Med Chem"},{"key":"3486_CR54","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1182\/blood.2023019706","volume":"143","author":"J Liu","year":"2024","unstructured":"Liu J, Li S, Wang Q, et al. Sonrotoclax overcomes BCL2 G101V mutation-induced venetoclax resistance in preclinical models of hematologic malignancy. Blood. 2024;143:1825\u201336.","journal-title":"Blood"},{"key":"3486_CR55","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS7087","volume":"42","author":"M Shadman","year":"2024","unstructured":"Shadman M, Kater AP, Woyach JA, et al. CELESTIAL-TNCLL: an ongoing, open-label, multiregional, phase\u00a03 study of sonrotoclax (BGB-11417) + zanubrutinib vs venetoclax + obinutuzumab for treatment-na\u00efve (TN) CLL. J Clin Oncol. 2024;42:TPS7087-TPS.","journal-title":"J Clin Oncol"},{"key":"3486_CR56","doi-asserted-by":"publisher","first-page":"3689","DOI":"10.2217\/fon-2022-0456","volume":"18","author":"CE Ryan","year":"2022","unstructured":"Ryan CE, Davids MS, Hermann R, et al. MAJIC: a phase\u00a0III trial of acalabrutinib\u00a0+\u00a0venetoclax versus venetoclax\u00a0+\u00a0obinutuzumab in previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. Future Oncol. 2022;18:3689\u201399.","journal-title":"Future Oncol"},{"key":"3486_CR57","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1182\/bloodadvances.2022008447","volume":"7","author":"A Naeem","year":"2023","unstructured":"Naeem A, Utro F, Wang Q, et al. Pirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second-site BTK mutations lead to resistance. Blood Adv. 2023;7:1929\u201343.","journal-title":"Blood Adv"},{"key":"3486_CR58","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2023-185852","volume":"142","author":"JA Woyach","year":"2023","unstructured":"Woyach JA, Brown JR, Ghia P, et al. Pirtobrutinib in post-cBTKi CLL\/SLL:~ 30\u00a0months follow-up and subgroup analysis with\/without prior BCL2i from the phase\u00a01\/2 BRUIN study. Blood. 2023;142:325.","journal-title":"Blood"},{"key":"3486_CR59","volume":"7","author":"JC Avalon","year":"2021","unstructured":"Avalon JC, Fuqua J, Miller T, et al. Pre-existing cardiovascular disease increases risk of atrial arrhythmia and mortality in cancer patients treated with Ibrutinib. Cardio-Oncol. 2021;7:38.","journal-title":"Cardio-Oncol"},{"key":"3486_CR60","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1016\/j.jacc.2019.07.056","volume":"74","author":"JE Salem","year":"2019","unstructured":"Salem JE, Manouchehri A, Bretagne M, et al. Cardiovascular toxicities associated with ibrutinib. J Am Coll Cardiol. 2019;74:1667\u201378.","journal-title":"J Am Coll Cardiol"},{"key":"3486_CR61","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1136\/heartjnl-2021-319110","volume":"108","author":"DH Lee","year":"2022","unstructured":"Lee DH, Hawk F, Seok K, et al. Association between ibrutinib treatment and hypertension. Heart. 2022;108:445\u201350.","journal-title":"Heart"},{"key":"3486_CR62","doi-asserted-by":"publisher","first-page":"E49","DOI":"10.1002\/ajh.26802","volume":"98","author":"N Dhopeshwarkar","year":"2023","unstructured":"Dhopeshwarkar N, Yang W, Hennessy S, et al. Bleeding with concomitant ibrutinib and oral anticoagulant therapy: a population-based cohort study. Am J Hematol. 2023;98:E49-e52.","journal-title":"Am J Hematol"},{"key":"3486_CR63","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1038\/s41375-020-0987-6","volume":"34","author":"DA Bond","year":"2020","unstructured":"Bond DA, Huang Y, Fisher JL, et al. Second cancer incidence in CLL patients receiving BTK inhibitors. Leukemia. 2020;34:3197\u2013205.","journal-title":"Leukemia"},{"key":"3486_CR64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e19016","volume":"42","author":"D Ramirez","year":"2024","unstructured":"Ramirez D, Chen L, Zhang J, Aldairy W, White WB. Risk of hypertension in patients with CLL\/SLL who participated in ALPINE: a post hoc analysis. J Clin Oncol. 2024;42:e19016.","journal-title":"J Clin Oncol"},{"key":"3486_CR65","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.3324\/haematol.2021.278901","volume":"107","author":"JR Brown","year":"2022","unstructured":"Brown JR, Byrd JC, Ghia P, et al. Cardiovascular adverse events in patients with chronic lymphocytic leukemia receiving acalabrutinib monotherapy: pooled analysis of 762 patients. Haematologica. 2022;107:1335\u201346.","journal-title":"Haematologica"},{"issue":"Suppl","key":"3486_CR66","doi-asserted-by":"publisher","first-page":"e47546cf","DOI":"10.1097\/01.HS9.0000969432.47546.cf","volume":"7","author":"S Hwang","year":"2023","unstructured":"Hwang S, Wang J, Tian Z, et al. P632: Comparison of treatment-emergent adverse events of acalabrutinib and zanubrutinib in clinical trials in B-cell malignancies: a systematic review and meta-analysis. Hemasphere. 2023;7(Suppl):e47546cf.","journal-title":"Hemasphere"}],"updated-by":[{"DOI":"10.1007\/s12325-026-03754-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000}}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03486-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03486-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03486-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T07:04:10Z","timestamp":1789023850000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03486-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,2]]},"references-count":66,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["3486"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03486-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,2]]},"assertion":[{"value":"16 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised due to update in figure 2","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s12325-026-03754-6","URL":"https:\/\/doi.org\/10.1007\/s12325-026-03754-6","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"John N. Allan: Consulting or advisory role: AbbVie, Adaptive Biotechnologies, ADC Therapeutics, AstraZeneca, BeOne Medicines, Ltd, Genentech, Janssen, Lilly, Merck, NeoGenomics, Pharmacyclics; Research funding: BeOne Medicines, Ltd, Celgene\/BMS, Genentech; Speakers bureau: AbbVie, BeOne Medicines, Ltd.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This article is based on previously conducted studies and does not contain any new studies with human participants or animals performed by the author.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}